Cambium Bio (ASX:CMBL)

Executive Summary

Cambium Bio Ltd is an Australian clinical-stage regenerative medicine company focused on developing biologic therapies for ophthalmology, orthopedics, and wound healing. The company leverages its proprietary human platelet lysate and mesenchymal stem-cell platforms to create innovative treatments. Its lead asset, Elate Ocular®, is a late-stage therapy for dry eye disease, targeting a large and underserved market. Cambium Bio is publicly traded on the ASX under the ticker CMBL and has raised approximately $150 million to support its pipeline development. With a Phase 3 trial underway for Elate Ocular, the company is poised for a pivotal value inflection point. Additionally, Cambium Bio is advancing preclinical and clinical programs for knee osteoarthritis and wound healing, diversifying its portfolio and addressing significant unmet medical needs. The company's strategic focus on regenerative medicine positions it well within the growing biologics landscape, and upcoming milestones are expected to drive near-term investor attention and potential regulatory progress.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data for Elate Ocular® in Dry Eye Disease65% success
• Q2 2027Regulatory Submission for Elate Ocular® (US/EU)50% success
• Q3 2026Phase 2 Interim Data for Knee Osteoarthritis Program70% success